@entity15833 -best hope for treatment of chronic XXXX ?

@entity1 @entity97 @entity16332 @entity24488 @entity1956 @entity1575 @entity17705 @entity3929 @entity15833 @entity157
BACKGROUND/AIMS: To evaluate the effectiveness of @entity15833 in @entity1 with chronic @entity1956 in a real life setting. MATERIALS AND METHODS: We performed a retrospective analysis of data from 164 @entity1 with chronic @entity1956 who were treated with @entity15833 . Eighty-six @entity1 (52.4%) were na  ve. Seventy-seven (46.9%) @entity1 were previously treated with anti-viral drugs, including standard interferon (n=4), pegylated (PEG) interferon (n=14), standard interferon together with @entity16332 (n=13), @entity16332 alone (n=41), @entity24488 (n=2), @entity16332 together with @entity24488 (n=1), and @entity17705 (n=2). Six @entity1 (3.7%) had @entity1575 before treatment of @entity15833 . RESULTS: The @entity1 who have @entity1956 viral DNA>104 copy/mL with chronic @entity1956 were included in the treatment of @entity15833 . Average follow up time was 30.31  14.33 months. @entity97 DNA negativity and @entity3929 aminotransferase (ALT) normalization were 86.5% and 71.3%, respectively, at the last visit. @entity1956 e-Antigen (HBeAg) seroconversion occurred in 11 (19.6%) out of 164 @entity1 . During the follow-up period, 4 (2.4%) @entity1 developed @entity1575 and in 5 (3%) @entity1 @entity157 ( @entity157 ) occurred out of 164 @entity1 . HBsAg seroconversion occurred in one @entity1 (0.6%). CONCLUSION: @entity15833 can be used safely and successfully in those @entity1 that were naive, experienced with immune modulators and/or antivirals, HBeAg-positive, and HBeAg-negative @entity1 .
